ArticleDigestive diseases and sciences2025
AHCTF1 Functions as an Oncogenic Factor and Promotes Tumor Progression in Hepatocellular Carcinoma.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to 'Insights on Advanced Age as a Predictor of TIPS Outcomes in Elderly Patients'.Digestive diseases and sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with poor prognosis due to late diagnoses and limited therapeutic targets. The AT-hook containing transcription factor 1 (AHCTF1) is linked to various cancers, yet its role in HCC is unclear.
aimsThis study aimed to investigate AHCTF1's role in HCC progression.
methodsBioinformatics analysis was performed using The Cancer Genome Atlas (TCGA) database to evaluate AHCTF1 expression in HCC and normal tissues. Differentially expressed genes (DEGs) associated with AHCTF1 were identified and analyzed for enrichment in key signaling pathways. The function of AHCTF1 in HCC was assessed in vitro by overexpressing AHCTF1 in Huh7 cells and knocking it down in HepG2 cells. The effect of AHCTF1 on tumor growth and metastasis in vivo was validated through xenograft tumor models and lung metastasis models.
resultsAHCTF1 was significantly upregulated in HCC tissues and correlated with poor prognosis. Bioinformatics analysis demonstrated that DEGs associated with AHCTF1 were enriched in the PI3K-Akt and Hedgehog signaling pathways, cell adhesion, and glycolysis. Overexpression of AHCTF1 enhanced HCC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) process, while knockdown of AHCTF1 suppressed these malignant phenotypes. These findings have been validated through xenograft and lung metastasis models, and AHCTF1 promotes tumor growth and metastasis.
conclusionThis study identifies AHCTF1 as a potential oncogenic factor, with high expression levels in HCC and a positive correlation with poor prognosis. AHCTF1 promotes tumor progression by enhancing the proliferation, migration, invasion, and EMT process of HCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.